Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Drug Metabolism And Disposition

• Publication date

  2016-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.116.070375PMID 27260150
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma.

  2016cited by this paper
• Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes

  2016cited by this paper
• Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

  2016influential reference
• SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid

  2015cited by this paper
• Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin

  2015influential reference
• A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study.

  2014cited by this paper
• Glucuronidation Converts Clopidogrel to a Strong Time‐Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions

  2014influential reference
• Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel

  2014cited by this paper
• OATP1B1-related drug–drug and drug–gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis

  2013cited by this paper
• Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

  2013cited by this paper
• Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers.

  2013cited by this paper
• PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8

  2012cited by this paper
• Rational Assessment of the Interaction Profile of Cerivastatin Supports its Low Propensity for Drug Interactions

  2012cited by this paper
• A Screening Study of Drug–Drug Interactions in Cerivastatin Users: An Adverse Effect of Clopidogrel

  2012influential reference
• Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.

  2012influential reference
• Pioglitazone

  2012cited by this paper
• Pioglitazone

  2012cited by this paper
• Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

  2011cited by this paper
• Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses

  2011cited by this paper
• Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite.

  2010cited by this paper
• CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe

  2009influential reference
• Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone

  2008influential reference
• No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.

  2008cited by this paper
• Pharmacokinetic Interactions with Thiazolidinediones

  2007influential reference
• Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.

  2006influential reference
• Effect of rifampicin on the pharmacokinetics of pioglitazone.

  2006cited by this paper
• SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

  2006cited by this paper
• GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

  2006cited by this paper
• Effect of gemfibrozil on the pharmacokinetics of pioglitazone

  2005influential reference
• Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics

  2005cited by this paper
• Effect of Clopidogrel and Ticlopidine on Cytochrome P450 2B6 Activity as Measured by Bupropion Hydroxylation

  2005cited by this paper
• Cyclosporine markedly raises the plasma concentrations of repaglinide

  2005cited by this paper
• Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics of Pioglitazone

  2005influential reference
• Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil

  2004cited by this paper
• Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

  2004cited by this paper
• Structure of Human Microsomal Cytochrome P450 2C8

  2004cited by this paper
• Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

  2003cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

  2003cited by this paper
• Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

  2003cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cited by this paper
• Gemfibrozil greatly increases plasma concentrations of cerivastatin

  2002cited by this paper
• Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.

  2002cited by this paper
• Mechanism-Based Inhibition of Human Cytochromes P450: In Vitro Kinetics and In Vitro—In Vivo Correlations

  2001influential reference
• Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus.

  2001cited by this paper
• An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

  2000influential reference
• Clinical Pharmacokinetics of Cerivastatin

  2000cited by this paper
• Clinical pharmacokinetics of pioglitazone

  2000influential reference
• Plasma concentrations of active simvastatin acid are increased by gemfibrozil

  2000cited by this paper
• Effect of itraconazole on cerivastatin pharmacokinetics

  1999cited by this paper
• Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole

  1998cited by this paper

• CYP2C8-Mediated Drug–Drug Interactions and the Factors Influencing the Interaction Magnitude

  2025cites this paper
• A genetic algorithm-based approach for the prediction of metabolic drug-drug interactions involving CYP2C8 or CYP2B6.

  2024cites this paper
• Utility of PBPK Modeling in Predicting and Characterizing Clinical Drug Interactions.

  2024cites this paper
• Clinical Pharmacology in Sarcoidosis: How to Use and Monitor Sarcoidosis Medications

  2024cites this paper
• Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug–Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil

  2023cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions

  2022cites this paper
• Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data

  2022cites this paper
• Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges

  2022cites this paper
• A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition

  2021cites this paper
• Caffeine modulates pharmacokinetic and pharmacodynamic profiles of pioglitazone in diabetic rats

  2021cites this paper
• Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease

  2021cites this paper
• Translational aspects of cytochrome P450‐mediated drug–drug interactions: A case study with clopidogrel

  2021cites this paper
• Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects

  2020cites this paper
• Clopidogrel drug interactions: a review of the evidence and clinical implications

  2020cites this paper
• Clinical evaluation of drug–drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers

  2020cites this paper
• Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients With Castration-resistant Prostate Cancer

  2020cites this paper
• Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

  2019cites this paper
• Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole

  2019cites this paper
• Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans

  2019influential citation
• Clopidogrel as a Perpetrator of Drug–Drug Interactions: A Challenge for Quantitative Predictions?

  2019cites this paper
• Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8

  2019cites this paper
• Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects

  2018cites this paper
• Mrp3 Transports Clopidogrel Acyl Glucuronide from the Hepatocytes into Blood

  2018cites this paper
• Thiazolidinediones and their drug interactions involving CYP enzymes

  2018cites this paper
• Pharmacokinetic Interactions and Pharmacogenetics of Clopidogrel, Prasugrel and Ticagrelor

  2018cites this paper
• Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions 

  2018cites this paper
• Human UGT2B7 is the major isoform responsible for the glucuronidation of clopidogrel carboxylate

  2018influential citation
• Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel

  2018cites this paper
• Drug metabolism and metabolite safety assessment in drug discovery and development

  2018cites this paper
• Pharmacogenetics of carboxylesterase 1

  2017cites this paper
• Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects

  2017cites this paper
• Ethnic Difference in the Pharmacodynamics‐efficacy Relationship of Dipeptidyl Peptidase‐4 Inhibitors Between Japanese and non‐Japanese Patients: A Systematic Review

  2017cites this paper
• Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir

  2017cites this paper
• Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8‐Mediated Metabolism of Montelukast in Humans

  2017cites this paper
• Assessment of preclinical pharmacokinetics and acute toxicity of pioglitazone and telmisartan combination

  2017cites this paper
• Letter: clinical response to pioglitazone in nonalcoholic steatohepatitis [NASH] treatment—use of pharmacokinetic surrogate

  2017cites this paper
• Letter: sprue‐like enteropathy associated with angiotensin II receptor blockers other than olmesartan

  2017cites this paper
• Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review

  2017cites this paper